Biotechnology News and Research

RSS

New gel promotes healing by gluing bone pieces together

A new material that fuses biological and synthetic substances at the molecular level speeds bone and cartilage repair. Its creators at the Technion-Israel Institute of Technology say laboratory studies have shown the new gel promotes healing by gluing bone pieces together and stimulating tissue development.

26 Dec 2004

Fluorescent colors used to separate cells visually

The latest holiday gifts being offered to the scientific community this season by scientists in the laboratory of Howard Hughes Medical Institute investigator Roger Y. Tsien come in a dazzling variety of hues -- cherry, strawberry, tangerine, tomato, orange, banana and honeydew. The color spectrum would make Pantone proud.

22 Dec 2004

Obesity drug codenamed AOD9604 highly successful in trials

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.

16 Dec 2004

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays, as these assays offer a more accurate representation of the real-life cell model than the traditional enzyme- or antibody-based assays.

13 Dec 2004

ID Biomedical announces strategic alliances for U.S. marketing and distribution of Fluviral vaccine

ID Biomedical Corporation announced today that it has signed long term marketing, distribution and minimum purchase agreements with three of the largest influenza vaccine wholesalers in the United States: Henry Schein, Inc.; AmerisourceBergen Corporation's Specialty Group; and McKesson Corporation.

6 Dec 2004

Episome vectors offer fresh angle to gene therapy

A European research team is seeking to overcome the early setbacks suffered by the promising new field of ‘gene therapy’ by developing a revolutionary delivery technique, known as ‘episome vectors’. This breakthrough could pave the way to treating hereditary diseases by injecting the body with healthy versions of damaged genes.

6 Dec 2004

Alliance to develop and commercialize fully-human anti-anthrax antibody

MDX-1303 was developed by Medarex using its UltiMAb Human Antibody Development System, and this antibody is currently in preclinical development by Medarex for use against human anthrax infection.

6 Dec 2004

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

“This important study shows the value of continuing periodic blood transfusions in preventing the serious and debilitating consequences of stroke,” says NHLBI Acting Director Barbara Alving. “At the same time, there are risks of chronic transfusions and the decision to continue with this treatment must be made on a case-by-case basis.”

6 Dec 2004

Venom from one of the world’s deadliest snakes is being developed as a new drug to treat heart failure

“The team has isolated a unique set of active molecules from Taipan venom and research shows they are extremely effective at easing the heart’s workload,” he said.

29 Nov 2004

Oral administration of saline spray may stop spread of influenza, tuberculosis, and SARS

Some individuals exhale many more pathogen-laden droplets than others in the course of ordinary breathing, scientists have found, but oral administration of a safe saline spray every six hours might slash exhalation of germs in this group by an average 72 percent.

29 Nov 2004

New possibilities for the use of VEGF in the treatment of Amyotrophic Lateral Sclerosis

ALS is an incurable, paralyzing neurodegenerative disorder that strikes 5 persons in every 100,000. The disease commonly affects healthy people in the most active period of their lives − without warning or previous family history.

29 Nov 2004

Manufacturers in the European active pharmaceutical ingredients market are struggling to overcome a variety of challenges

Manufacturers in the crowded and highly fragmented European active pharmaceutical ingredients (API) market are struggling to overcome a variety of challenges. One of the most pressing of these is the problem of overcapacity.

29 Nov 2004

Biotechnology News and Research

New gel promotes healing by gluing bone pieces together

Fluorescent colors used to separate cells visually

Obesity drug codenamed AOD9604 highly successful in trials

Pharmaceutical, biotechnology and drug discovery companies are increasingly turning their attention to cell-based assays

ID Biomedical announces strategic alliances for U.S. marketing and distribution of Fluviral vaccine

Episome vectors offer fresh angle to gene therapy

Alliance to develop and commercialize fully-human anti-anthrax antibody

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

Children with sickle cell disease who are at risk for a stroke need ongoing blood transfusions to reduce their risk

Venom from one of the world’s deadliest snakes is being developed as a new drug to treat heart failure

Oral administration of saline spray may stop spread of influenza, tuberculosis, and SARS

New possibilities for the use of VEGF in the treatment of Amyotrophic Lateral Sclerosis

Manufacturers in the European active pharmaceutical ingredients market are struggling to overcome a variety of challenges

Discovery of a new cancer gene, which, when damaged, may promote prostate cancer

Breakthrough HIV research wins prestigious industry award

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

Transport route explain why peanuts are one of the most allergenic foods

Scientists enticed back to Australia to tackle major health challenges

The first test in humans of a bioartificial kidney

Researchers find that berries inhibit growth of harmful intestinal bacteria

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News